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Summary 
Since  tumor necrosis  factor  (TNF)-a,  interferon  (IFN)-%  and  transforming growth  factor 
(TGF)-[3 have  all  been  shown  to  be  specific inhibitors  of early human  hematopoiesis,  we 
wanted to investigate the interactions of these three cytokines on very primitive human adult 
bone marrow CD34 § +CD38- hematopoietic progenitor cells, using a pre-colony-forming cell 
(pre-CFC) assay, which detects the effects of these cytokines on the initial phases of the differ- 
entiation of these primitive progenitors, which are unresponsive to interleukin (IL)  3  alone. 
Surprisingly, TNF-cx was a very potent stimulator of the proliferation of CD34 + +CD38- cells 
and was the most potent synergistic factor for the IL-3-induced proliferation of these cells of all 
cytokines tested (IL-1, IL-6, granulocyte colony-stimulating factor, kit ligand). TNF-o~ was the 
only cytokine that, as a single added factor, induced substantial proliferation in CD34 + +CD38- 
cells in the presence of IL-3, except for kit ligand, which induced very limited proliferation. 
TNF-c~, moreover, induced a high degree of resistance to the inhibitory effects of TGF-13 in a 
dose-dependent way. The inhibitory effects oflFN-% however, were not affected by the pres- 
ence of TNF-ot. We hypothesize that in situations of hematopoietic stress, TNF-oL may abro- 
gate the inhibitory effect of ambient TGF-[3 in the bone marrow microenvironment to allow 
primitive stem cells to proliferate and differentiate in response to an increased demand for ma- 
ture blood cells. 
T 
he  proliferation and  differentiation of primitive  he- 
matopoietic progenitor cells are regulated by direct in- 
teraction of these cells with bone marrow stroma and by 
the stimulatory and inhibitory effects of cytokines present 
in the microenvironment of the bone'fnarrow (1). 
Among cytokines inhibiting hematopoiesis, the action of 
TGF-[3 on progenitor cells has been characterized the best 
(2-5). The sensitivity of progenitor cells to the inhibitory 
effects of TGF-[3 is inversely correlated with their matura- 
tion  stage:  the  proliferation and  differentiation of a  very 
primitive progenitor are profoundly inhibited by TGF-[3 
(2-4), whereas  more mature  progenitors are  even stimu- 
lated  in  some  circumstances  (5).  We  recently identified 
IFN-~/as a selective inhibitor of  primitive human CD34 ++ 
CD38- progenitor cells  (6).  TNF-o~ is a pleiotropic cyto- 
kine  that is predominantly produced by macrophages  (7) 
and has been shown by many investigators to be a bifunc- 
tional regulator of the  proliferation and  differentiation of 
more mature hematopoietic progenitor cells, depending on 
the  cytokines present in  the  culture medium  and  on the 
degree of progenitor cell enrichment (8-10). A number of 
reports from the  same  group have  recently demonstrated 
that TNF-ot is another direct and selective inhibitor of very 
primitive stem cells in the human (11-13) and routine (14) 
systems.  Others,  however, have demonstrated stimulatory 
effects of TNF-cx on more primitive progenitors (10,  15). 
The aim of this work is to characterize the interactions 
of the  three  aforementioned hematopoietic inhibitors  on 
purified human  CD34++CD38 -  cells,  which  have  been 
shown  to  contain  the  most primitive identifiable human 
progenitors (6, 16). We used a two-stage pre--colony-form- 
ing cell (pre-CFC) assay, since this allows the characteriza- 
tion of the effects of these cytokines on the initial phases of 
the proliferation of CD34++CD38 -  cells  (6,  17).  Surpris- 
ingly, TNF-o~ turned out to be a very powerful stimulator 
of the prohferation of CD34§  -  cells and to induce 
resistance to the inhibitory effects of TGF-~3 but not IFN-~/. 
Materials and Methods 
Bone .Marrow Cells.  Bone marrow samples were aspirated by 
sternal puncture from hematologica]ly normal patients undergo- 
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to the regulations of the Ethics Committee of the University of 
Antwerp, in tubes containing 2 ml IMDM (Gibco Laboratories, 
Paisley, UK) and 5 U/ml preservative-free heparin (Novo Indus- 
tries, Copenhagen, Denmark). Cells were separated on a lymphocyte 
separation medium (LSM; Boehringer Mannheim GmbH, Penz- 
berg,  Germany) density gradient and washed twice.  Remaining 
B,  BC were lysed using an NH4C1 containing  lysing solution. 
Cytokines and mAbs.  Supernatant  of  the  43A1  hybridoma 
(IgG3, kindly donated by Dr. H.J. Biihring, University of Ti.ibin- 
gen, TiJbingen, Germany) was used as a source ofanti-CD34 (18). 
FITC-conjugated rabbit  anti-mouse  lg  (ab')2  fragments  were 
purchased from Dako  (Glostrup, Denmark), and PE-conjugated 
anti-CD38  (IgG1)  antibodies as well as isotype-specific control 
antibodies were  purchased from Becton Dickinson (Erembode- 
gem,  Belgium). Monoclonal neutralizing anti-TNF-(x(IgG), ir- 
relevant control  antibody  (IgG),  and ultrapure  natural TGF-I3 
(10  6 U/mg) were purchased from Genzyme Corp.  (Cambridge, 
MA).  rhTNF-ix (108 U/rag),  IFN-'y (2.107  U/rag),  IL-6  (108 
U/rag), and IL-1  (5.10  v U/mg) were obtained from Boehringer 
Mannheim GmbH  (Penzberg,  Germany). rbG-CSF,  GM-CSF, 
and IL-3 were kind gifts  of Dr.  S.  C.  Clark (Genetics Institute, 
Cambridge, MA). Erythropoietin (epo 105 U/mg) was purchased 
from Cilag (Brussels, Belgium). 
Cell Sorting and Pre-CFU Assay.  Labeling of low density bone 
marrow cells for CD34 and CD38 and isolation of CD34§  - 
cells by flow c-ytometric cell sorting were performed as described 
previously (6).  Primary liquid cultures of CD34+§  cells 
were performed in 96-well flat-bottom plates in duplicate at 100 
cells/well in IMDM, 10% FCS, and combinations of the follow- 
ing recombinant human cytokines:  100 ng/ml IL-1,  200 U/ml 
IL-6, 30 U/ml IL-3, 100 ng/ml kit ligand (KL), and varying con- 
centrations ofTNF-ix, TGF-13, and IFN-~. After 14 d of primary 
culture, the number of cells in each well was counted using an in- 
verted microscope at a magnification of 250, after which the cells 
were  harvested,  washed  three  times in IMDM with  10%  FCS, 
and plated in secondary methylcellulose cultures (0.9%)  supple- 
mented with 20% FCS, 1% BSA, 10 -5 M  2-ME, 30 U/ml IL-3, 
100  ng/ml  G-CSF,  100  ng/ml  GM-CSF,  and  2  U/ml  epo, 
which were optimal concentrations for colony formation in pre- 
liminary experiments. These cultures were microscopically scored 
for colony formation after 14 d of culture at 37~  in 7.5% O 2 and 
5% CO2 in a fully humidified incubator. To ascertain that the ef- 
fects  of TNFr(x in these  experiments were  direct, some experi- 
ments were performed at a single-cell level. CD34  + +CD38- cells 
were  sorted  at  1  cell/well in 96-well V-bottomed plates  (two 
plates per cytokine combination). In test sorts using fluorescent 
microbeads,  on average  <2%  of the wells contained no beads, 
and no wells were  detected that contained more than one bead. 
Each  well  contained  100  Ixl  of culture  medium  consisting  of 
IMDM,  10% FCS,  IL-3, and KL  (concentrations as in the pri- 
mary cultures described above) and either no TNF-(x or TNF-c( 
at  1 ng/ml. After 14  d  of culture (37~  5% 0 2,  5% CO  2 in a 
fully humidified incubator), the number of wells where growth 
had occurred was scored using an inverted microscope. 
Statistics.  In all experiments, Student's t test for paired sam- 
ples was used. 
Results 
TNF-ee  Stimulates  the  Proliferation  and  Differentiation  of 
CD34++CD38  -  Cells.  We  have  previously  shown  that 
CD34++CD38 -  cells require at least the presence of IL-3, 
KL,  and  either  G-CSF,  IL-1,  or  IL-6  to  proliferate  and 
generate secondary CFC,  Optimal proliferation is obtained 
in the  presence  of IL-3,  KL,  and two  of the  other  afore- 
mentioned synergistic factors  (6).  Since  TNF-e~  has  been 
reported to inhibit the proliferation of very primitive pro- 
genitor cells (11-14), we first investigated whether TNF-ot 
would inhibit the proliferation and differentiation of opti- 
mally stimulated CD34++CD38 -  cells in a  two-stage  pre- 
CFC  assay.  As shown in Fig.  1 A,  addition of TNF-ot to 
the  liquid primary  cultures  of CD34++CD38 -  cells  sup- 
ported  by  an  optimal  combination  of cytokines,  that  is, 
IL-3,  KL,  IL-1,  and  IL-6,  induced  a  very  substantial in- 
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Figure 1.  Dose response of the effect of TNF-ix on the expansion of 
CD34++CD38 -  human bone marrow cells (A) and on the generation of 
secondary CFC from CD34++CD38 - human bone marrow cells (B) after 
14 d of liquid culture supported by IL-3, IL-I, IL-6, and KL in the ab- 
sence (triangles) and presence (circles) of TGF-[~ (5 ng/ml). Results are ex- 
pressed as the percentage of control cultures without TNF-cl and TGF-I3 
(horizontal line). Significant differences compared with control cultures are 
indicated with an asterisk, n =  13 except for TNF-c( 1 ng/ml, where n = 
20, for TNF-0t 5 ng/ml, where n =  24, and for TNF-ix 25 ng/ml, where 
n =  7 (A); n =  7 except for TNF-(x  1 ng/ml, where  n =  12, and for 
TNF-(x 5 ng/ml, where n =  16 (B). 
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culture.  The  stimulatory  action  of TNF-c~  was  maximal 
between  0.5  and 2.5  ng/rnl  and  decreased  at higher  con- 
centrations.  Maximal  cell  expansion  in  the liquid  cultures 
was on average increased  18-fold (P =  0.0001).  This huge 
increase  in  cell  number was paralleled  by a  somewhat less 
substantial increase in CFC output (Fig. 1 B). The maximal 
increase in the number of secondary CFC was on average 
13-fold  at  1  ng/ml  of TNF-e~  (P  =  0.0001).  Secondary 
colonies consisted mostly ofmacrophage and mixed granu- 
locyte--macrophage colonies, with a minority of  pure gran- 
ulocytic, erythroid, and mixed myeloid-erythroid colonies. 
No preferential  production of any kind of CFC was noted 
after  culture  in  the  presence  of TNF--a  (not  shown).  At 
higher concentrations  of TNF-a,  no significant difference 
in CFC output was found compared with cultures without 
TNF-o~,  although  cell  expansion  after  14  d  of primary 
culture  was  significantly  higher  (fourfold  at  5  ng/ml, 
P  <0.05).  To test whether this was caused by a more rapid 
differentiation  of primitive progenitor cells in the presence 
of TNF-ci, secondary semisolid cultures were plated after 7 
instead of 14 d  of primary liquid culture in the presence of 
IL-3, KL, IL-1, IL-6, and 5  ng/ml TNF-ci.  Indeed, when 
the cells  were plated in semisolid cultures after 7 d of liquid 
culture,  a  16-fold increase  in CFC  output was seen in the 
presence of  TNF-~x compared with cultures without TNF-oe, 
indicating  that  TNF-ci  promotes  faster  proliferation  and 
differentiation ofCD34++CD38 -  cells (not shown). 
Since TNF-c~ has such a potent stimulatory effect on op- 
timally stimulated primitive progenitor cells, we next investi- 
gated whether  TNF-oe would be  able  to induce prolifera- 
tion  of CD34++CD38-  in  the presence  of IL-3 alone,  to 
which these cells are normally unresponsive (Table 1). As we 
have previously shown (6), addition of  single synergistic fac- 
tors  (IL-1, IL-6, G-CSF, KL) to cultures ofCD34++CD38 - 
cells  supported  by IL-3 alone  does  not induce  any prolif- 
eration  or  generation  of secondary  CFC,  except  for  the 
combination of IL-3 plus KL, where very limited prolifera- 
Table  1.  Effect  of TNF-ce (1 ng/ml) on the Prediferation and 
Differentiation of CD34++ CD38  -  Cells Supported by IL-3 
and by IL-3 and KL 
Cell number*  CFC number*  Colonies/96 wells* 
IL-3 
IL-3 +  TNF 
P 
IL-3 +  KL 
IL-3 +  KL 
+  TNF 
P 
19.3+7  0.3 +  0.3  0 +  0 
473 +  95  25 +  6  14.7  +  1,4 
0.000l  0.000l  0.0001 
58+7  0.7 +0.3  1 +  1 
11,379  _+ 1,035  88 •  48  19.8 +  3 
0.0001  0.0001  0.0001 
tion is seen.  As shown in Table  1, TNF-o~ indeed induces 
substantial  proliferation  and generation  of secondary CFC 
in cultures supported by IL-3 alone and by IL-3 and KL. It 
is clear from these data that TNF-oL is much more potent as 
a  single  synergistic  factor  for  IL-3--stimulated  CD34  ++ 
CD38-  cells  than  KL.  Furthermore,  as shown in Table  1, 
this effect was a direct one, since it could be reproduced in 
single-cell  cultures  of CD34++CD38 -  cells.  In  the  pres- 
ence of neutralizing anti-TNF-r  antibodies,  no effect was 
seen (not shown). In the absence oflL-3, no proliferation is 
seen in  cultures  supported by TNF-e~ alone  or by combi- 
nations  of TNF-o~ with  IL-1,  IL-6, KL,  and  G-CSF  (not 
shown). TNF-oL is thus a potent direct synergistic factor for 
very primitive progenitor cells that are unresponsive to IL-3 
alone. 
TNF-ee  Reverses  the  Inhibitory  Effects  of TGF-~  but  Not 
IFN-T.  TGF-[3  is  well  known  as  a  potent  inhibitor  of 
hematopoietic progenitor cells  (2-4). Maximum inhibition 
is  obtained  at  a  concentration  of 2.5-5  ng/ml  (Fig.  2, A 
and B). As shown in Fig.  1 A  (number of cells after 14 d of 
primary liquid culture) and Fig. 1 B (CFC output after 14 d 
of liquid culture),  a concentration of 0.1  ng/rnl of TNF-c~ 
was sufficient to restore cell proliferation and the output of 
CFC  to  baseline  values  of cultures  without  TGF-[3  and 
TNF-cl.  Moreover,  at  higher  concentrations  of TNF-oe, 
that  is,  from  5  ng/ml  on,  the  dose--response  curves  of 
TNF-Ix  in  the  presence  and  absence  of TGF-13,  respec- 
tively,  coincide.  In the  presence  of an  optimal  inhibitory 
concentration ofTGF-I3, 1 ng/ml of TNF-oe stimulates the 
proliferation  of CD34++CD38 -  cells  supported  by  IL-3, 
IL-1, IL-6, and KL by N50-fold. Although from Fig.  1, in 
which increases in cell number and CFC output were cal- 
culated as a percentage of  control without TGF-13 and TNF-oq 
one  would  be  tempted  to  conclude  that  TNF-ci  induces 
complete resistance to the inhibitory effects of TGF-I3, this 
is not the case when the relative inhibitions induced by dif- 
ferent concentrations of TGF-13 in the presence of  0, 1, and 
5  ng/ml  TNF-Ix are analyzed.  As shown in Fig.  2  A  (cell 
number after  14 d  of primary liquid culture)  and Fig.  2  B 
(CFC output after  14 d  of primary liquid culture),  there is 
an  upward  shift  of the  dose-response  curve  of TGF-[3  in 
the  presence  of increasing  concentrations  of TNF-e~,  but 
significant,  albeit limited,  relative  inhibition  still  occurs  at 
higher concentrations of TGF-I3. 
IFN-'y was recently identified by our group as a potent 
direct inhibitor ofCD34++CD38 -  cells (8). As with TGF-13, 
the inhibitory effect of IFN-~/is specific for more primitive 
progenitor cells.  In contrast to TGF-I3, however,  an opti- 
mal concentration of IFN-'y (1,000 U/ml) induces the same 
relative inhibition of the proliferation and differentiation of 
CD34++CD38 -  cells  in  the  presence  compared with  the 
absence of TNF-c~, respectively (Fig. 3). 
*Results expressed as number cells and CFC, respectively, obtained af- 
ter 14 d of  liquid culture per 100 input CD34++CD38 - cells; n = 3. 
~Results expressed as number of positive wells per 96 wells in single- 
cell cultures of CD34++CD38- after 14 d of culture; n =  6. 
Discussion 
This work demonstrates that TNF-oe is a potent stimula- 
tor of the proliferation of very primitive adult hematopoie- 
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the expression ofCD34++CD38 -  cells (A) and on the generation of sec- 
ondary CFC from CD34++CD38  cells  (B) after 14 d of liquid culture 
supported by IL-3, IL-1, IL-6, and KL in the absence (triangles)  or pres- 
ence of 1 ng/ml (circles) or 5 ng/ml (squares)  of TNF-0t, respectively.  Re- 
sults are expressed as the percentage of control cultures without TGF-[3. 
Significant differences compared with control cultures are indicated with 
an asterisk, n  =-  7,  except for TGF-[3 5 ng/ml and TNF-e~ 0 ng/ml, 
where n =  27, TGF-13 5 ng/ml and TNF-c~ 1 ng/ml, where n =  20, and 
TGF-13 5 ng/ml and TNF-o~ 5 ng/ml, where n =  24 (A); n =  7, except 
for TGF-]3 5 ng/ml and TNF-cr 0 ng/ml, where n =  27, TGF-[3 5 ng/ 
ml and TNF-~ 1 ng/ml, where n =  20, and TGF-13 5 ng/ml and TNF-~ 
5 ng/ml, where n =  24 (B). 
tic  progenitor  cells,  as  defined  by  a  high  expression  of 
CD34 and the absence of CD38 expression. As we and oth- 
ers have previously shown (6, 16), these cells represent 1-5% 
of bone  marrow  CD34 +  cells, need  multiple growth  fac- 
tors,  including at least IL-3 and KL, for proliferation, and 
do  not  form  colonies  in  classic semisolid assays,  but  give 
rise to  secondary CFC  after liquid culture in the presence 
of appropriate combinations of growth factors. The absence 
of growth in the presence of IL-3 and the very low level of 
growth in the presence of IL-3 plus KL indicates that they 
are indeed very primitive cells (19). 
TNF-or  is  the  most  potent  synergistic  factor  for  the 
IL-3-induced proliferation of these  cells  of the  cytokines 
tested (KL,  IL-1,  IL-6,  and  G-CSF)  and is the  only cyto- 
kine,  next  to  KL,  that  as a  single added agent  can  induce 
proliferation in CD34++CD38-  cells cultured in the pres- 
ence  of  IL-3.  Moreover,  the  combination  of  IL-3  plus 
TNF-cx is much more potent than the combination of IL-3 
Figure 3.  Relative inhibitory effect oflFN-"/ (1,000 U/ml) on the ex- 
pression and on the output of secondary CFC of CD34++CD38  bone 
marrow cells after 14 d of liquid culture supported by IL-3, IL-1, IL-6, 
and KL, in the absence and presence of 5 ng/ml TNF-et. Results are ex- 
pressed as a percentage compared with control cultures without  IFN-~/. 
Significant differences  compared with control cultures are indicated with 
an asterisk, n =  6. 
plus KL. Quantitatively, this stimulatory effect is far greater 
than  any  stinmlatory  effect  of TNF-cx  on  hematopoietic 
progenitors reported in the literature thus far. According to 
the  results  of the  single-cell culture  experiments  in  this 
study, the synergistic effect of TNF-cx on the proliferation 
of CD34 + +CD38-  cells is a direct one. 
Stimulatory effects of TNF-cx on very early hematopoi- 
etic progenitors have  been  reported before,  but  these  re- 
ports  dealt with  populations  that  were  still responsive  to 
IL-3 alone  (10,  15).  On the  other hand,  although  Rusten 
et al.  (11)  showed  stimulatory effects of TNF-oL on IL-3- 
and  GM-CSF-responsive  human  progenitors,  the  same 
authors demonstrated an inhibitory effect of TNF-ot medi- 
ated by the p75 TNF receptor on very primitive high pro- 
liferative potenital (HPP)  CFC in the murine  (14)  and hu- 
man  (11)  system.  Functionally, the  cells used in  the  latter 
reports were similar to the cells described in this report, in 
that they have an HPP  and are dependent on the presence 
of multiple growth factors for their proliferation. There  is 
agreement, however, on the heterogenicity of the response 
of hematopoietic progenitor ceils to TNF-oL, depending on 
their differentiation stage, phenotype, and on the cytokines 
present in the culture medium. The fact that in our experi- 
ments only the effect on the initial phases of the prolifera- 
tion  of  CD34++CD38 -  cells  were  assessed  might  have 
played a  role.  This  hypothesis  is  substantiated by  existing 
evidence  that  TNF-cx  recruits  a  more  primitive subset  of 
progenitors  (15)  while  inducing  a  differentiation  block 
downstream  (10,  20).  Since  the  relative  increase  in  the 
number  of secondary CFC  induced by TNF-&  compared 
with  cultures without  TNF-ot is larger after 7  d  of liquid 
culture  than  after  14  d  of liquid  culture,  it  follows  that 
TNF-ot induces more rapid differentiation together with a 
stimulation of the proliferation of very primitive progeni- 
tors. 
In this report, it is also shown for the first time that even 
very  low  concentrations  (0.1  ng/ml)  of TNF-er  alleviate 
++  708  TNF-cx Stinmlates Primitive CD34  CD38- Hematopoietic Progenitors the profound inhibitory effect of TGF-[3 on the prolifera- 
tion of very primitive human progenitor cells.  At these low 
concentrations  of TNF-~x,  a profound inhibitory effect of 
TGF-~ is still  seen when compared with  cultures  without 
TGF-~, but, remarkably, at higher concentrations of  TNF-ot, 
a high degree of resistance  against the effects of TGF-I3 is 
induced.  Other cytokines, such as IL-1, IL-6, G-CSF, and 
basic fibroblast growth factor (21-23),  have been shown to 
partially  abrogat  e  the  inhibitory  effects  of TGFq3.  In our 
experiments,  however, TGF-~ was still  profoundly inhibi- 
tory, despite the presence of many of these factors.  On the 
other hand,  the inhibitory effects of IFN-~/ (6) were unaf- 
fected by the presence of TNF-ci. 
Stern  cells  are  known  to  be  inhibited  and  "protected" 
from the stimulatory effects of  ambient hematopoietic stimu- 
lators  by TGF-[3,  produced  autocrinely  or paracrinely  by 
stem  cells  and  the  surrounding  bone  marrow  stroma  (24, 
25).  It is  our hypothesis that in situations  of increased de- 
mand for mature blood cells,  TNF-ci,  a  typical inflamma- 
tory cytokine, induces resistance to the inhibitory effects of 
TGF-13 so that these cells  become responsive to the prolif- 
erative  effects  of other  cytokines.  Exhaustion  of the  stem 
cells  could be prevented by the fact that the selective inhib- 
itory  effect  of another  inflammatory  cytokine,  IFN-2t,  is 
not opposed by TNF-0e. 
In conclusion, TNF-oe is a very potent synergistic stimu- 
lator  of very  primitive  human  hematopoietic  progenitor 
cells  and  induces  resistance  in  these  cells  to  the  effect  of 
TGF-13 but not IFN-~. 
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